Moderna (MRNA.US), an American company best known for its Covid-19 vaccine, was observed by many investors in recent days. Moderna shares have been gaining for several sessions in a row, climbing to new all-time high. Over the past week, the price has already increased by over 30%. From where did such strong price increases come from?
Before the session on July 21 (Wednesday), the company will join the S&P 500 index. The announcement from the index operator appeared last Thursday and led to increased interest in the company's shares during Friday's session during which the local volume high was also recorded. However, this does not change the fact that the upward movement continues, as the company may also benefit from the growing number of new coronavirus cases, and it should be remembered that in many underdeveloped countries the percentage of vaccinated people is still very low.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app
Moderna stocks (MRNA.US) broke above the $ 300 barrier today and price continues to climb higher. The gains clearly picked up after the price broke above the line drawn at the recent highs. If sellers manage to regain control, then the line should act as the first major support. Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
